Compare VERU & NSYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VERU | NSYS |
|---|---|---|
| Founded | 1971 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.2M | 40.1M |
| IPO Year | 1996 | 1996 |
| Metric | VERU | NSYS |
|---|---|---|
| Price | $2.63 | $12.21 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $22.50 | N/A |
| AVG Volume (30 Days) | ★ 278.7K | 14.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 80.85 |
| EPS | N/A | ★ 0.09 |
| Revenue | ★ $16,296,958.00 | $14,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $134.56 |
| Revenue Growth | N/A | ★ 7.01 |
| 52 Week Low | $2.05 | $6.50 |
| 52 Week High | $7.33 | $18.01 |
| Indicator | VERU | NSYS |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 39.55 |
| Support Level | $2.12 | $11.94 |
| Resistance Level | $2.67 | $15.35 |
| Average True Range (ATR) | 0.14 | 1.07 |
| MACD | 0.06 | -0.18 |
| Stochastic Oscillator | 65.75 | 18.16 |
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Nortech Systems Inc is a United States-based electronic manufacturing services company. It offers value-added engineering, technical, and manufacturing services and support, including project management, design, testing, prototyping, manufacturing, supply chain management, and post-market services. The company's manufacturing and engineering services include complete medical devices, printed circuit board assemblies, wire and cable assemblies, and complex higher-level electro-mechanical assemblies. It operates in the Medical, Aerospace, Defense, and Industrial markets, with key revenue coming from medical-related markets.